AstraZeneca has received US clearance for its proposed acquisition of Alexion Pharmaceuticals.
The company said on Friday that the deal has now cleared the US Federal Trade Commission review.
The acquisition has already received regulatory clearance in Canada, Brazil, and Russia, among others. Additional regulatory clearances are pending, including the UK, EU and Japan.
Marc Dunoyer, executive director and chief financial officer of AstraZeneca, said: “These clearances further advance us towards closing our acquisition of Alexion. We remain focused on the next chapter for AstraZeneca and Alexion, building on our combined expertise in immunology and precision medicines and our shared ambition to bring more innovative medicines to patients worldwide.”
The pharmaceuticals giant announced in December 2020 that it had agreed to buy Alexion in a $39bn deal to expand its scientific presence in immunology. It said at the time that the deal was expected to close in the third quarter of 2021.
